Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer

NCT07669779 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT07669779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07669779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Recruiting
Start date
July 10, 2026
Completion date
May 30, 2029
Enrollment
348 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer (nsclc)